Five drugs, in­clud­ing two No­var­tis ther­a­pies, win EMA en­dorse­ment

As is cus­tom, an EMA pan­el on Fri­day is­sued its week­ly rec­om­men­da­tions on mar­ket­ing ap­pli­ca­tions sub­mit­ted by drug de­vel­op­ers. This week, the agency backed the use of five new ther­a­pies — in­clud­ing two No­var­tis drugs — but is­sued no neg­a­tive re­views.

No­var­tis’ S1P drug for re­laps­ing forms of mul­ti­ple scle­ro­sis (MS) drug, Mayzent (known chem­i­cal­ly as sipon­i­mod), which was ap­proved by the FDA in March — has been giv­en the nod by the EMA. The Swiss drug­mak­er al­ready sells its oth­er MS drug, Gilenya, in both re­gions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER